Pemphigus Vulgaris Market (2025 - 2033) Size, Share & Trends Analysis Report By Therapy Type (Anti-CD20 Monoclonal Antibodies, Systemic Corticosteroids, Topical therapies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts

Pemphigus Vulgaris Market Summary

The global pemphigus vulgaris market size was estimated at USD 481.3 million in 2024 and is projected to reach USD 975.2 million by 2033, growing at a CAGR of 8.2% from 2025 to 2033. Improved diagnostics & early detection, advancements in treatment modalities, and increasing R&D investments drive market growth.

Pemphigus vulgaris is a rare, severe autoimmune blistering disease primarily affecting the skin and mucous membranes. It accounts for approximately 70% of all pemphigus cases globally. Reported incidence varies globally by geography and ethnicity, ranging from 0.5 to 50 new cases per million people yearly.

Governments and foundations worldwide have initiated several programs to support individuals suffering from PV. For instance, in December 2023, in the U.S., the PAN Foundation, in partnership with the International Pemphigus & Pemphigoid Foundation (IPPF), offered financial assistance to PV patients. Eligible individuals are provided up to USD 6,600 annually to cover expenses and support services for patients & their caregivers.

Market Concentration & Characteristics

Significant advancements in artificial intelligence (AI) have enhanced the diagnostic accuracy for PV. For instance, a study published in the Journal of Indian Academy of Oral Medicine & Radiology on Artificial Intelligence in Medicine demonstrated that AI algorithms, including logistic regression, k-nearest neighbors, and random forest models, accurately distinguished PV lesions from healthy oral mucosa.

In the pemphigus vulgaris industry, the barriers to market entry are high due to several structural and regulatory factors. PV is classified as a rare disease, which limits patient pool size and makes clinical trial recruitment both costly and time-consuming. In addition, the complexity of PV requires long trial durations and specialized diagnostic criteria, raising research costs. Strict regulatory requirements for orphan drugs, while providing incentives, also impose rigorous safety and efficacy standards before approval. Furthermore, the high cost of biologics and emerging therapies and limited reimbursement frameworks in some countries create financial hurdles for new entrants.

The pemphigus vulgaris market is gradually expanding across multiple geographies, driven by increasing disease awareness, improved diagnostic capabilities, and the introduction of advanced therapies. Historically, PV incidence has been higher in regions such as the Middle East, India, and Mediterranean countries. Still, recent reports indicate rising diagnosis rates in North America, Europe, and East Asia due to better physician education and patient screening.

Therapy Type Insights

The anti-CD20 monoclonal antibodies (rituximab) segment dominated the pemphigus vulgaris industry with the largest revenue share of 42.3% 2024 and is expected to grow at the fastest CAGR over the forecast period. It has recently been recognized as a first-line treatment for moderate-to-severe PV. Rituximab offers several advantages, including the ability to control disease activity with spaced intervals, facilitating the tapering and withdrawal of systemic corticosteroids, thereby reducing long-term side effects. Clinical evidence indicates an 80% chance of achieving drug-free remission within two years of treatment. 

The topical therapies segment is expected to grow over the forecast period. The growth is driven by the increasing adoption of topical therapies for pemphigus vulgaris, particularly in patients with mild or localized lesions. These therapies, primarily topical corticosteroids such as clobetasol propionate, offer effective lesion control while minimizing systemic side effects commonly associated with oral corticosteroids. Patient preference for localized, easy-to-apply treatments enhances adherence, while their cost-effectiveness makes them accessible across diverse healthcare settings.

Distribution Channel Insights

The hospital pharmacies segment held the largest market revenue share of 81.6% in 2024. Hospital Pharmacies serve as the largest segment, as PV is a rare and severe autoimmune disease that often requires specialized care, intravenous or infusion-based treatments, and close monitoring by dermatologists and immunologists. Patients with moderate-to-severe PV frequently need hospital-based administration of therapies such as rituximab, systemic corticosteroids, and intravenous immunoglobulin (IVIG), which cannot be effectively managed through retail pharmacies or home care. The availability of trained healthcare professionals, infusion facilities, and supportive services within hospital pharmacies ensures safe and effective treatment delivery, thereby increasing patient access and adherence.

The other segment is expected to grow at the fastest CAGR over the forecast period. The rapid growth of online and infusion pharmacies drives the market. In addition, the rise of telemedicine and digital health platforms has further supported patient monitoring and prescription management, enhancing adherence and treatment outcomes. This increasing adoption of non-traditional distribution channels accelerates market growth by expanding access to PV therapies beyond traditional hospital settings.

Regional Insights

North America dominated the pemphigus vulgaris market with a revenue share of 38.1% 2024. The growth is driven by the region's advanced healthcare infrastructure, physician expertise in autoimmune and dermatological disorders, and availability of biologic therapies for PV. High patient awareness and proactive screening for rare diseases enable early diagnosis, improving treatment outcomes. In addition, North America benefits from robust government and nonprofit initiatives, including orphan drug incentives and patient support programs, which reduce financial and logistical barriers to therapy access.

U.S. Pemphigus Vulgaris Market Trends

The U.S. dominated the North America pemphigus vulgaris industry with a revenue share of 89.5% in 2024. The country's leadership in research and development for rare autoimmune diseases, rapid adoption of innovative therapies, and comprehensive patient support systems drive the market growth.

Europe Pemphigus Vulgaris Market Trends

The Europe pemphigus vulgaris industry is projected to grow during the forecast period. The market is driven by increasing prevalence and improved diagnosis of autoimmune diseases, which have raised demand for effective PV treatments. Advancements in biologic therapies are providing more targeted and effective options compared with traditional corticosteroid-based treatments.

Asia Pacific Pemphigus Vulgaris Market Trends

The Asia Pacific pemphigus vulgaris industry is expected to witness the fastest CAGR of 9.2% over the forecast period. The growth is driven by increasing healthcare expenditure, expanding access to advanced diagnostic facilities, and growing awareness of autoimmune diseases among healthcare professionals and patients. Emerging economies are rapidly adopting modern treatment options, including biologics and biosimilars, which were previously limited to urban centers.

The Japan pemphigus vulgaris market is expected to witness a robust growth driven by its well-developed healthcare system, early regulatory approvals for biologics and biosimilars, and strong government support for rare disease research and treatment. High patient awareness and adherence to structured PV management guidelines ensure timely diagnosis and optimal therapy administration.

Key Pemphigus Vulgaris Company Insights

Some key companies in the pemphigus vulgaris market include CELLTRION INC., Genentech, Inc., and others.

• Genentech, Inc. focuses on discovering, developing, producing, and commercializing therapies for patients with serious or life-threatening medical conditions, including autoimmune disorders such as PV.

Recent Developments

• In June 2025, CELLTRION INC. received FDA approval for its Rituxan biosimilar Truxima to treat moderate to severe PV, marking its fifth adult indication. On the same day, Pfizer's Ruxience and Amgen's Riabni also secured FDA approvals for PV injections.

• In May 2025, Scinai Immunotherapeutics Ltd. announced a webinar to discuss unmet treatment needs in pemphigus vulgaris and highlight PINCELL’s PC111, a novel monoclonal antibody targeting soluble Fas ligand.

Pemphigus Vulgaris Market Report Scope

Global Pemphigus Vulgaris Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pemphigus vulgaris market report based on therapy type, distribution channel, and region:

• Therapy Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Anti-CD20 monoclonal antibodies (rituximab)

  • Systemic corticosteroids

  • Conventional steroid-sparing immunosuppressants

  • Intravenous immunoglobulin (IVIG) - adjunct

  • Topical therapies

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait